Teladoc Health experienced a challenging third quarter in 2025, with consolidated revenues decreasing by 2% to $626.4 million and adjusted EBITDA falling by 16% to $69.9 million. The company reported a net loss of $49.5 million, or $0.28 per share, which included a non-cash goodwill impairment charge.
Consolidated revenue decreased by 2% to $626.4 million in Q3 2025 compared to Q3 2024.
Net loss for Q3 2025 was $49.5 million, or $0.28 per share, an increase from $33.3 million in Q3 2024.
Adjusted EBITDA decreased by 16% to $69.9 million in Q3 2025.
Integrated Care segment revenue increased by 2% while BetterHelp segment revenue decreased by 8%.
The financial outlook is based on current market conditions and expectations, with a focus on advancing strategic priorities and growth initiatives.
Analyze how earnings announcements historically affect stock price performance